endo-BCN-Val-Cit-PAB-MMAE is a synthetic antibody-drug conjugate (ADC) coupled to a BCN group. It contains a protease-sensitive Val-Cit dipeptide and an MMAE payload. The MMAE is a synthetic antineoplastic agent. The BCN group can react with azide-tagged compounds or biomolecules.
Usually ships within 24 hours.